Shailender Bhatia, MD

Shailender Bhatia, MD

Associate Professor
Department of Medicine
Division of Oncology

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Ave W, CE2-128
Seattle, WA 98109-1023

Admin Contact

Samantha Lepidi

Specialty / Expertise

  • Skin Cancers (Melanoma, Merkel Cell Cancer)
  • Kidney Cancers
  • Immunotherapy
  • Intra-tumoral therapy
  • Targeted therapy

Research Interests

Dr. Bhatia’s research efforts are mostly focused on clinical trials that aim at improving outcomes in skin cancers (especially Melanoma and Merkel cell carcinoma) and Kidney cancers. He is especially interested in those novel therapeutic approaches that stimulate the immune system against cancer and those that target therapy to the tumors in order to spare unnecessary toxicity.

Current Research Projects

A pharmacodynamic study of intratumoral injection of Glucopyranosyl Lipid A (GLA), a Toll-like receptor 4 (TLR4) agonist, in patients with Merkel Cell Carcinoma

A Multicenter Phase II Trial of intratumoral pIL-12 electroporation in advanced stage cutaneous and in transit malignant melanoma

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of BMS-982470 (Recombinant Interleukin 21, rIL-21) in combination with Ipilimumab in Subjects with Unresectable Stage III or Stage IV Melanoma

A Phase II study of intratumoral injection of Interleukin-12 plasmid and in vivo electroporation in patients with Merkel Cell Cancer An Exploratory Study of the Biologic Effects of BMS-936558 (Anti-PD-1 Monoclonal Antibody) Treatment in Subjects with Advanced Melanoma (Unresectable or Metastatic)


Dr. Bhatia received his MBBS (equivalent to MD) degree at the All India Institute of Medical Sciences (AIIMS) in New Delhi, INDIA and completed his Internal Medicine Internship and Residency at the University of Connecticut Health Center, Farmington, CT. He completed his Post-Doctoral fellowship in Hematology/Oncology at the University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA.

Selected Publications

Bhatia S, Heath E, Puzanov I, Miller W, Quinn D, Curti B, Gordon M, Ernstoff M, Hausman D, Hunder N, Thompson JA. Phase 1/2 study of recombinant IL-21 (rIL-21) plus sorafenib as second or third-line therapy for metastatic renal cell cancer. Journal for Immuno-Therapy of Cancer 2014 2:2.

Chapuis AG, Afanasiev OK, Iyer JG, Paulson KG, Parvathaneni U, Hwang JH, Lai I, Roberts IM, Sloan HL, Bhatia S, Shibuya KC, Gooley T, Desmarais C, Koelle DM, Yee C, Nghiem P. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res. 2014 Jan 1;2(1):27-36.

Blom A, Bhatia S, Pietromonaco S, Koehler K, Iyer JG, Nagase K, Paulson K, Sabath DE, Nghiem P. Clinical utility of a circulating tumor cell assay in Merkel cell carcinoma. J AM Acad Dermatol. 2013 Dec 30. pii: S0190-9622(13)01173-0.

Liao J, Parvathaneni U, Laramore G, Thompson J, Bhatia S, Futran N, Bhrany A, Hawes S, Ladra M. Fast Neutron Radiotherapy for Primary Mucosal Melanomas of the Head and Neck. Head and Neck. 2013 Jul 12. doi: 10.1002/hed.23428.

Miller NJ, Bhatia S, Parvathaneni U, Iyer JG, Nghiem P. Emerging and Mechanism-Based Therapies for Recurrent or Metastatic Merkel Cell Carcinoma. Current Treatment Options in Oncology. 2013 Jun; 14(2):249-63. doi: 10.1007/s11864-013-0225-9

Bhatia S, Moon J, Margolin KA, Weber JS, Lao CD, Othus M, Aparicio AM, Ribas A, Sondak VK. Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512. PLOS ONE 7(11): e48787. doi: 10.1371/journal.pone.0048787. 2012.

Paulson KG, Iyer JG, Blom A, Warton EM, Sokil M, Yelistratova L, Schuman L, Nagase K, Bhatia S, Asgari MM, Nghiem P. Systemic Immune Suppression Predicts Diminished Merkel Cell Carcinoma-Specific Survival Independent of Stage. J Inves Dermatol. 2012 Nov 29. doi: 10.1038/jid. 2012.388.

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65.

Bhatia S, Thompson JA. Systemic therapy for metastatic melanoma in 2012: dawn of a new era. J Natl Compr Canc Netw. 2012 Mar; 10(3):403-12.

Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, Farrar EA, Bhatia S, Sabath DE, Cao J, Li Y, Yee C. Transferred Melanoma-Specific CD8+ T Cells Persist, Mediate Tumor Regression and Acquire Central Memory Phenotype. Proc Natl Acad Sci, U.S.A. 2012 Mar 20; 109(12):4592-7. Epub 2012 Mar 5.

Bhatia S, Afanasiev O, Nghiem P. Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer. Curr Oncol Rep. 2011 Dec; 13(6):488-97. Review.

Bhatia S, Tykodi SS, Thompson JA. Treatment of Metastatic Melanoma: an overview. Oncology (Williston Park). 2009 May; 23(6):488-96.

Bhatia S, Huber BR, Upton MP, Thompson JA. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother. 2009 Feb-Mar;32(2):203-5

Bhatia S, Thompson JA. Temsirolimus in patients with advanced renal cell carcinoma: an overview. Adv Ther. 2009 26(1):55-67.

Thompson JA, Curti BC, Redman BG, Bhatia S, Weber JS, Agarwala SS, Sievers EL, Hughes SD, DeVries TA, Hausman DF. Phase 1 Study of Recombinant Interleukin-21 in Patients with Metastatic Melanoma and Renal Cell Carcinoma. J Clin Oncol. 2008 Apr 20;26(12):2034-9

Bhatia S, Bauer F, Bilgrami S. Candidiasis - Associated Hemophagocytic Lymphohistiocytosis in Patient Infected with Human Immunodeficiency Virus. Clin Infect Dis. 2003 Dec 1;37(11):e161-6

Last updated: February 2014